Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

In a world-first human trial, Australian researchers have achieved a major milestone in heart disease prevention with a new ...

Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model to carry out vital ...

Researchers say the breakthrough is an important step forward in being able to carry out medical research without the use of ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 ...

Scientists have discovered a groundbreaking technology that is showing remarkable success in significantly reducing bad ...

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the ...

Labroots invites you to the 9th Annual Event in the CRISPR Virtual Event Series 2026 taking place on October 28th, 2026! This event will continue the conversation of the abilities of CRISPR-based ...